Next Article in Journal
Asian Pigeonwing Plants (Clitoria ternatea) Synergized Mesenchymal Stem Cells by Modulating the Inflammatory Response in Rats with Cisplatin-Induced Acute Kidney Injury
Next Article in Special Issue
Antidiabetic Potential of Novel 1,3,5-Trisubstituted-2-Thioxoimidazloidin-4-One Analogues: Insights into α-Glucosidase, α-Amylase, and Antioxidant Activities
Previous Article in Journal
Hydroxysafflor Yellow A Phytosomes Administered via Intervaginal Space Injection Ameliorate Pulmonary Fibrosis in Mice
Previous Article in Special Issue
New Quinoline–Urea–Benzothiazole Hybrids as Promising Antitubercular Agents: Synthesis, In Vitro Antitubercular Activity, Cytotoxicity Studies, and In Silico ADME Profiling
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 11
10.3390/ph15111395
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Biological Evaluation of a Fused Structure of Indolizine and Pyrrolo[1,2-c]pyrimidine: Identification of Its Potent Anticancer Activity against Liver Cancer Cells

by
Seonghyeon Nam
†,
Yechan Lee
†,
So-Hyeon Park
,
Wan Namkung
* and
Ikyon Kim
*
College of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Korea
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2022, 15(11), 1395; https://doi.org/10.3390/ph15111395
Submission received: 8 October 2022 / Revised: 3 November 2022 / Accepted: 10 November 2022 / Published: 12 November 2022
(This article belongs to the Special Issue Heterocyclic Compounds and Their Application in Therapy)
Browse Figures
Versions Notes

Abstract

:
A highly efficient approach to a new indolizine scaffold fused with pyrrolo[1,2-c]pyrimidine was achieved via one-pot three-component coupling followed by an oxidative cyclization reaction. The simple two-step sequence allowed rapid access to various tetracyclic compounds from commercially available starting materials with the formation of five new bonds. Here, we observed the effects of these compounds on cell viability in HepG2, H1299, HT29, AGS, and A549 cancer cell lines. Interestingly, this fused scaffold had more potent anticancer activity in hepatocellular carcinoma HepG2 and Huh7 cells than other cancer cells. In particular, 5r strongly decreased cell viability in HepG2 and Huh7 cells with an IC50 value of 0.22 ± 0.08 and 0.10 ± 0.11 µM, respectively, but had a very weak inhibitory effect on the cell viability of other cancer cell lines. In addition, 5r significantly inhibited cell migration and induced apoptosis in HepG2 and Huh7 cells via the activation of caspase-3 and cleavage of PARP in a dose-dependent manner. Notably, the co-treatment of 5r with gemcitabine resulted in the significant additional inhibition of cell viability in HepG2 and Huh7 cells. Our results suggest that 5r could be used to develop new chemotype anticancer agents against liver cancers.

1. Introduction

Polyheterocycles are widely found in both natural products and artificial materials while exhibiting a wide range of biological and optophysical properties. Owing to their versatile usages in many different fields, efforts to expand the polyheterocyclic chemical space via design and synthesis are highly valuable [1,2]. As part of our research interest on novel polyheterocyclic structures, we designed several new heterocyclic scaffolds having two or more pharmacophores, hoping that these new fused polycycles might have intriguing properties that had not been previously discovered with each heterocyclic ring system. Along this line, we developed several efficient synthetic strategies of novel fused heterocycles [3,4,5], which enabled us to investigate their biological and/or photophysical activities (Figure 1) [6].
Liver cancer is one of the most common causes of cancer death worldwide and the fifth most common cancer in the United States [7]. Based on the announcement of Globocan 2020, 905,677 new liver cancer patients occurred in 2020 and 830,180 deaths were confirmed. The incidence of liver cancer is generally higher in developing countries and risk factors include hepatitis B virus, hepatitis C virus, fatty liver disease, smoking, alcoholic cirrhosis, obesity, and diabetes [8,9]. With respect to the surgical treatment of liver cancer, only 5 to 15% of patients in the early stage without cirrhosis can undergo surgery. In addition, commonly used drugs develop resistance within six months and long-term use causes toxicity problems and reduced drug effectiveness [10]. Despite advances in new therapeutic techniques for screening, prevention, diagnosis, and treatment, the mortality rate of the patients with liver cancer continues to rise [11]. Therefore, there is an urgent need for the development of new anticancer agents to overcome many limitations in the treatment of liver cancer. In this study, we generated a new polycyclic heteroaromatic scaffold consisting of indolizine and pyrrolo[1,2-c]pyrimidine and examined its anticancer effect on five different cancer cells.
In 2017, Hulme and co-workers reported a direct one-pot three-component assembly route to 1-cyano-3-amino-2-arylindolizines 1 (Scheme 1a) [12]. Inspired by this work, we came up with the general idea that a new indolizine-fused heteroaromatic system 3 would be constructed via 2 by using a (hetero)aryl aldehyde in the three-component coupling process followed by oxidative cyclization (Scheme 1b). In this context, we planned to employ pyrrole-2-carboxaldehyde in the first step to gain access to 4. The subsequent oxidative cyclization of 4 with an aldehyde leads to an indolizine skeleton fused with pyrrolo[1,2-c]pyrimidine 5. As indolizine [13] and pyrrolo[1,2-a]pyrimidine [14,15] have been frequently employed in material and medicinal sciences, we anticipated to discover new biochemical functions with this new skeleton. Here, we wish to describe the synthesis and biological evaluation of this tetracyclic fused scaffold. While we were preparing this manuscript, the Hulme group disclosed the synthesis and photophysical properties of indolizino[3,2-c]isoquinoline 7 via the intermediate 6 [16].

2. Results and Discussion

2.1. Synthesis and Cell Inhibitory Activity of Pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizines

By following Hulme’s procedure, we were able to make 4 from the reaction of pyridine-2-acetonitrile with pyrrole-2-carboxaldehyde and TMSCN in the presence of DBU at 60 °C in 79% yield (Scheme 2). The reaction of 4 with DMFDMA in toluene went smoothly to yield the basic tetracyclic skeleton 8. The oxidative cyclization for the synthesis of the pyrimidine ring in 5 was realized by the treatment of 4 with benzaldehyde in the presence of K2CO3 in DMSO under microwave heating at 130 °C for 30 min to afford 5a in 89% yield. It should be mentioned that this new tetracyclic heteroaromatic structure was constructed in two steps with the formation of five new bonds, illustrating the efficiency of our method. Interestingly, when 9 was allowed to react with aldehydes under similar conditions, pentacyclic indolizine–γ-carboline hybrids 10a–d were obtained as a result of the involvement of the C3 carbon of the indole in the oxidative cyclization instead of the nitrogen of the indole to form the pyridine moiety [17,18].
Under the optimal conditions, various aldehydes were allowed to react with 4 to furnish derivatives 5 (Table 1). Electron-poor as well as electron-rich aryl moieties were installed at the C5 position of this heterocyclic system in good yields. Indolizine–pyrrolo[1,2-c]pyrimidine hybrids bearing heteroaromatic rings such as pyridine, indole, furan, and thiophene at the C5 site were readily accessed as well.
The preliminary biological screening of these compounds revealed that this class of compounds exhibited strong inhibitory activity against HepG2 and H1299 cells out of the five cancer cells evaluated (Table 2). In particular, stronger anticancer activities were observed with compounds 5k, 5l, and 5n in HepG2 cells, having pyridine, indole, and thiophene at the C5 site of this scaffold.
Thus, more derivatives were prepared in a similar way and their anticancer activities against HepG2 and Huh7 cells were evaluated (Table 3). In general, heterocycles or aryl groups with ortho- or meta-substituent(s) at the C5 position seemed beneficial for enhanced anticancer activity. We were pleased to find that 5r bearing a 2-hydroxyphenyl at the C5 site had more potency than 5n. Interestingly, 5s with a 3-hydroxyphenyl moiety at the C5 position exhibited less cytotoxicity than 5r, indicating that the orientation of the hydroxyl in this scaffold is critical for potent activity.
More analogs of 5r were synthesized to examine the effects of the substituent(s) of the 2-hydroxyphenyl moiety on inhibitory activity (Table 4). Unfortunately, an additional methoxyl or chlorine on the ring did not increase the potency.

2.2. Effect of 5r on Cell Viability in HepG2, Huh7, AGS, H1299, A549, HaCaT, NIH3T3, and HEK293T Cells

To further investigate the concentration-dependent effect of the most potent compound (5r) on cell viability in other cancer cell lines, we observed the cytotoxic effect of 5r in HepG2, Huh7 hepatocellular carcinoma, AGS gastric adenocarcinoma, H1299 non-small cell lung carcinoma, and A549 lung carcinoma cell lines. As shown in Figure 2A,B, 5r potently reduced cell viability in HepG2 and Huh7 cells with an IC50 value of 0.22 ± 0.08 and 0.10 ± 0.11 µM, respectively. However, 5r had a weak effect on the other cancer cell lines, AGS, H1299, and A549 (Figure 2C–E). In addition, 5r also weakly decreased cell viability in non-cancerous cells including HaCaT, NIH3T3, and HEK293T cells (Figure 2F–H). These results suggest that 5r can be developed as a selective anticancer agent against liver cancer.

2.3. Inhibitory Effect of 5r on Cell Migration in HepG2 and Huh7 Cells

To investigate the inhibitory effect of 5r on cell migration, we performed an in vitro wound-healing assay in HepG2 and Huh7 cells. As shown in Figure 3, 5r significantly inhibited cell migration in a dose-dependent manner in both HepG2 and Huh7 cells.

2.4. 5r Induces Activation of Caspase-3 and PARP Cleavage in HepG2 and Huh7 Cells

To investigate whether 5r induces apoptosis in HepG2 and Huh7 liver cancer cells, we observed caspase-3 activation and the cleavage of PARP, a hallmark of apoptosis, in HepG2 and Huh7 cells. Interestingly, 5r potently increased caspase-3 activity (green) in both HepG2 and Huh7 cells (Figure 4A,B). In addition, caspase-3 activity was significantly increased by 5r in a dose-dependent manner, and the increased activity of caspase-3 was fully inhibited by Ac-DEVD-CHO, a specific caspase-3 inhibitor (Figure 4C,D). In the case of PARP cleavage, 5r increased the expression level of cleaved PARP in a dose-dependent manner in HepG2 and Huh7 cells (Figure 4E–H). These results suggest that 5r showed a significant anticancer effect by inducing apoptosis via the activation of caspase-3 and cleavage of PARP in HepG2 and Huh7 cells.

2.5. 5r Dose Not Significantly Affect Cell Cycle of HepG2 Cells

To determine the effect of 5r on the cell cycle of HepG2 cells, we performed a flow cytometry analysis using propidium iodide staining. As shown in Figure 5, 5r significantly increased the ratios in the Sub-G1 (apoptotic peak) phase but did not affect the ratio in the G2/M phase in HepG2 cells. In the case of 5r, the G0/G1 phase decreased from 64.6% to 29.3% and the Sub-G1 phase increased from 24.1% to 56.9% compared with the control. These results suggest that 5r strongly increases apoptosis without a significant effect on cell cycle arrest.

2.6. Combination Effect of 5r with Gemcitabine on Cell Viability in HepG2 and Huh7 Cells

Gemcitabine exhibits broad activity in a variety of solid tumors and has shown potent activity against hepatocellular carcinoma cells in preclinical studies [19,20]. However, gemcitabine alone showed a response rate of 0–20% in phase 2 clinical trials [21,22,23,24,25,26]. To investigate the combinational effect of 5r with gemcitabine, a cell viability analysis was performed in HepG2 and Huh7 cells. As shown in Figure 6, interestingly, the co-treatment of 5r with gemcitabine showed an additional effect rather than a synergistic effect. These results suggest that 5r-based drug development could potentially increase the therapeutic effect in liver cancer.

3. Materials and Methods

3.1. General Methods

Unless specified, all reagents and starting materials were purchased from commercial sources and used as received without purification. “Concentrated” refers to the removal of volatile solvents via distillation using a rotary evaporator. “Dried” refers to pouring onto, or passing through, anhydrous magnesium sulfate followed by filtration. Flash chromatography was performed using silica gel (230−400 mesh) with hexane, ethyl acetate, and dichloromethane as the eluents. All reactions were monitored by thin-layer chromatography on 0.25 mm silica plates (F-254) visualized with UV light. Melting points were measured using a capillary melting point apparatus. Then, 1H and 13C NMR spectra were recorded on a 400 MHz NMR spectrometer and were described in terms of chemical shifts, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), coupling constant in hertz (Hz), and number of protons (see Supplementary Materials). HRMS was measured with an electrospray ionization (ESI) and Q-TOF mass analyzer.

3.1.1. Synthesis of 4

To a mixture of 2-pyridylacetonitrile (472.1 μL, 4.23 mmol, 1.0 equiv) and pyrrole-2-carboxaldehyde (443.2 mg, 4.66 mmol, 1.1 equiv) in EtOH (10 mL) were added TMSCN (794.4 μL, 6.35 mmol, 1.5 equiv) and DBU (631.3 μL, 4.23 mmol, 1.0 equiv) at rt. After being stirred at 60 °C for 24 h, the reaction mixture was suction-filtered to give the desired product 4. The filtrate was further purified by silica gel column chromatography (hexane:EtOAc:dichloromethane = 5:1:2) to give 4. Overall, 4 was obtained in 79% yield (742.7 mg) as a brown solid.
Pharmaceuticals 15 01395 i0013-Amino-2-(1H-pyrrol-2-yl)indolizine-1-carbonitrile (4). Brown solid, m.p.: 192.7–193.6 °C (742.7 mg, 79%); 1H NMR (400 MHz, DMSO-d6) δ 10.96 (s, 1H), 8.23 (d, J = 7.0 Hz, 1H), 7.48 (d, J = 8.8 Hz, 1H), 7.04–6.97 (m, 1H), 6.93–6.89 (m, 1H), 6.87 (t, J = 6.8 Hz, 1H), 6.48 (s, 1H), 6.20–6.15 (m, 1H), 4,98 (s, 2H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 133.5, 125.8, 123.8, 123.0, 121.2, 119.3, 118.2, 116.6, 112.6, 109.0, 107.6, 76.3; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C13H11N4 223.0978, found 223.0970.

3.1.2. General Procedure for the Synthesis of 5

A mixture of 4 (25.0 mg, 0.11 mmol, 1.0 equiv), PhCHO (13.3 μL, 0.13 mmol, 1.2 equiv), and K2CO3 (28.9 mg, 0.22 mmol, 2.0 equiv) in DMSO (2 mL) was stirred at 130 °C (microwave heating was used) for 30 min. The reaction mixture was diluted with dichloromethane (5 mL) and washed with water (5 mL). The water layer was extracted with dichloromethane (5 mL) one more time. The organic layer was dried over MgSO4 and concentrated under reduced pressure to give the crude residue, which was purified by silica gel column chromatography (hexane/EtOAc:dichloromethane = 7:1:2) to afford 5a (30.7 mg, 89%) as a yellow solid.
Pharmaceuticals 15 01395 i0025-Phenylpyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5a). Yellow solid, m.p.: 232.5–233.2 °C (30.2 mg, 89%); 1H NMR (400 MHz, CDCl3) δ 8.72 (d, J = 6.8 Hz, 1H), 7.93–7.87 (m, 2H), 7.74 (d, J = 8.8 Hz, 1H), 7.64–7.57 (m, 2H), 7.29–7.23 (m, 1H), 7.15 (d, J = 3.2 Hz, 1H), 6.94–6.87 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 144.1, 138.0, 134.0, 130.6, 129.0, 128.7, 128.5, 127.6, 125.2, 123.5, 117.3, 116.4, 115.1, 114.4, 112.6, 111.4, 101.2, 72.1; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H13N4 309.1135, found 309.1135.
Pharmaceuticals 15 01395 i0035-(4-Methoxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5b). Yellow solid, m.p.: 189.2–189.8 °C (23.8 mg, 64%); 1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 6.8 Hz, 1H), 7.87 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 8.8 Hz, 1H), 7.66–7.62 (m, 1H), 7.25–7.21 (m, 1H), 7.16–7.12 (m, 1H), 7.10 (d, J = 8.4 Hz, 2H), 6.92–6.86 (m, 2H), 3.93 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 161.3, 144.1, 137.9, 130.2, 128.7, 127.7, 126.4, 125.1, 123.5, 117.4, 116.6, 115.0, 114.4, 114.3, 112.6, 111.2, 101.1, 72.0, 55.5; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C21H15N4O 339.1240, found 339.1234.
Pharmaceuticals 15 01395 i0045-(3,4-Dimethoxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5c). Yellow solid, m.p.: 209.3–209.9 °C (29.2 mg, 72%); 1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 6.8 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.68–7.64 (m, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.42 (s, 1H), 7.26–7.20 (m, 1H), 7.15–7.10 (m, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.93–6.84 (m, 2H), 4.00 (s, 3H), 3.97 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 151.0, 149.3, 144.1, 138.0, 128.6, 127.8, 126.5, 125.1, 123.6, 121.6, 117.4, 116.5, 115.1, 114.5, 112.6, 111.7, 111.3, 111.1, 101.2, 72.1, 56.2, 56.1; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C22H17N4O2 369.1346, found 369.1336.
Pharmaceuticals 15 01395 i0055-(3,5-Dimethoxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5d). Green solid, m.p.: 238.8–239.5 °C (36.1 mg, 89%); 1H NMR (400 MHz, CDCl3) δ 8.72 (d, J = 6.8 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.66–7.62 (m, 1H), 7.28-7.20 (m, 1H), 7.15–7.10 (m, 1H), 7.01 (s, 2H), 6.93–6.84 (m, 2H), 6.67 (s, 1H), 3.88 (s, 6H); 13C{1H} NMR (100 MHz, CDCl3) δ 161.2, 143.9, 138.0, 135.6, 128.4, 127.6, 125.3, 123.6, 117.4, 116.5, 115.1, 114.6, 112.6, 111.6, 106.7, 102.7, 101.2, 72.1, 55.7; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C22H17N4O2 369.1346, found 369.1345.
Pharmaceuticals 15 01395 i0065-(3,4,5-Trimethoxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5e). Brown solid, m.p.: 244.8–245.4 °C (28.0 mg, 64%); 1H NMR (400 MHz, CDCl3) δ 8.73 (d, J = 6.8 Hz, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.68–7.62 (m, 1H), 7.26–7.20 (m, 1H), 7.13 (s, 3H), 6.93–6.86 (m, 2H), 3.97 (s, 3H), 3.95 (s, 6H); 13C{1H} NMR (100 MHz, CDCl3) δ 153.7, 143.9, 140.0, 138.0, 129.2, 128.4, 127.7, 125.3, 123.6, 117.4, 116.4, 115.2, 114.5, 112.7, 111.5, 106.0, 101.3, 72.1, 61.0, 56.4; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C23H19N4O3 399.1452, found 399.1449.
Pharmaceuticals 15 01395 i0075-(Naphthalen-2-yl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5f). Yellow solid, m.p.: 218.2–218.9 °C (26.0 mg, 66%); 1H NMR (400 MHz, CDCl3) δ 8.77 (d, J = 7.2 Hz, 1H), 8.44 (s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 8.00–7.93 (m, 3H), 7.77 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 2.8 Hz, 1H), 7.64–7.59 (m, 2H), 7.31–7.27 (m, 1H), 7.19 (d, J = 3.6 Hz, 1H), 6.95–6.90 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 144.1, 138.1, 134.2, 133.0, 131.3, 128.8, 128.7, 128.6, 127.9, 127.8, 127.6, 127.0, 125.4, 125.3, 123.6, 117.5, 116.5, 115.3, 114.5, 112.7, 111.6, 101.3, 72.2; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C24H15N4 359.1291, found 359.1285.
Pharmaceuticals 15 01395 i0085-(Naphthalen-1-yl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5g). Yellow solid, m.p.: 120.5–121.1 °C (31.9 mg, 81%); 1H NMR (400 MHz, CDCl3) δ 8.73 (d, J = 6.8 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 7.2 Hz, 1H), 7.78 (d, J = 9.6 Hz, 1H), 7.68 (t, J = 8.0 Hz, 1H), 7.56 (t, J = 7.1 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.42 (d, J = 7.2 Hz, 1H), 7.31–7.26 (m, 1H), 7.20-7.16 (m, 1H), 6.97-6.93 (m, 1H), 6.90 (t, J = 6.7 Hz, 1H), 6.82–6.77 (m, 1H); 13C{1H} NMR (100 MHz, CDCl3) δ 143.4, 138.1, 133.8, 131.2, 130.9, 128.7, 128.4, 127.7, 127.4, 127.3, 126.7, 125.5, 125.4, 124.7, 123.7, 117.5, 116.5, 115.2, 114.9, 112.7, 111.9, 101.2, 72.3; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C24H15N4 359.1291, found 359.1290.
Pharmaceuticals 15 01395 i0095-(4-Chlorophenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5h). Yellow solid, m.p.: 230.0–230.8 9 °C (27.5 mg, 73%); 1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 6.8 Hz, 1H), 7.87 (d, J = 7.2 Hz, 2H), 7.75 (d, J = 8.8 Hz, 1H), 7.62–7.54 (m, 3H), 7.29 (d, J = 7.6 Hz, 1H), 7.19–7.13 (m, 1H), 6.97–6.88 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 142.9, 138.2, 136.7, 132.4, 130.1, 129.3, 128.5, 127.7, 125.4, 123.5, 117.5, 116.3, 115.4, 114.1, 112.8, 111.6, 101.4, 72.2; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H12ClN4 343.0745, found 343.0719.
Pharmaceuticals 15 01395 i0105-(4-Bromophenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5i). Yellow solid, m.p.: 227.6–228.4 °C (32.8 mg, 77%); 1H NMR (400 MHz, CDCl3) δ 8.68 (d, J = 6.8 Hz, 1H), 7.79 (d, J = 8.0 Hz, 2H), 7.76–7.69 (m, 3H), 7.57 (d, J = 2.8 Hz, 1H), 7.30–7.23 (m, 1H), 7.13 (d, J = 3.2 Hz, 1H), 6.94–6.87 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 142.9, 138.1, 132.9, 132.3, 130.2, 128.4, 127.7, 125.5, 125.0, 123.5, 117.4, 116.3, 115.4, 112.8, 111.6, 101.4, 72.2; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H12BrN4 387.0240, found 387.0233.
Pharmaceuticals 15 01395 i011Methyl 4-(12-cyanopyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizin-5-yl)benzoate (5j). Yellow solid, m.p.: 231.2–231.7 °C (25.8 mg, 64%); 1H NMR (400 MHz, CDCl3) δ 8.73 (d, J = 6.8 Hz, 1H), 8.26 (d, J = 8.0 Hz, 2H), 8.01 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.8 Hz, 1H), 7.59 (s, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.19–7.14 (m, 1H), 6.97–6.88 (m, 2H), 4.00 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 166.3, 142.8, 138.3, 138.1, 131.9, 130.2, 128.7, 127.8, 125.6, 123.6, 117.5, 116.3, 115.5, 114.1, 112.8, 111.8, 101.5, 72.3, 52.5; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C22H15N4O2 367.1190, found 367.1185.
Pharmaceuticals 15 01395 i0125-(Pyridin-2-yl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5k). Green solid, m.p.: 192.0–192.6 °C (29.6 mg, 87%); 1H NMR (400 MHz, CDCl3) δ 8.99–8.95 (m, 1H), 8.83–8.79 (m, 1H), 8.77 (d, J = 6.8 Hz, 1H), 8.43 (d, J = 8.0 Hz, 1H), 7.95 (t, J = 7.0 Hz, 1H), 7.74 (d, J = 9.0 Hz, 1H), 7.51–7.43 (m, 1H), 7.33-7.26 (m, 1H), 7.22–7.18 (m, 1H), 7.01–6.97 (m, 1H), 6.94 (t, J = 6.9 Hz, 1H); 13C{1H} NMR (100 MHz, CDCl3) δ 152.9, 148.2, 140.0, 138.5, 136.8, 127.7, 127.6, 125.6, 124.9, 124.5, 123.5, 117.2, 117.0, 116.4, 115.1, 112.7, 112.5, 100.9, 72.2; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C19H12N5 310.1087, found 310.1069.
Pharmaceuticals 15 01395 i0135-(1H-Indol-2-yl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5l). Brown solid, m.p.: 270.8–271.4 °C (27.1 mg, 71%); 1H NMR (400 MHz, CDCl3) δ 9.46 (s, 1H), 8.72 (d, J = 6.8 Hz, 1H), 8.22–8.18 (m, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 9.2 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.25-7.19 (m, 1H), 7.17–7.13 (m, 1H), 7.03 (t, J = 3.2 Hz, 1H), 6.92 (t, J = 6.8 Hz, 1H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 138.2, 137.2, 136.3, 129.8, 128.5, 127.8, 127.6, 127.2, 124.8, 124.7, 122.1, 120.4, 117.3, 116.5, 116.3, 115.4, 113.8, 112.2, 110.4, 105.7, 100.6, 71.0; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C22H14N5 348.1244, found 348.1215.
Pharmaceuticals 15 01395 i0145-(Furan-2-yl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5m). Yellow solid, m.p.: 238.1–238.6 °C (29.5 mg, 90%); 1H NMR (400 MHz, CDCl3) δ 8.73 (d, J = 6.8 Hz, 1H), 8.38 (d, J = 2.8 Hz, 1H), 7.77–7.69 (m, 2H), 7.45 (d, J = 3.2 Hz, 1H), 7.30–7.27 (m, 1H), 7.17 (d, J = 4.0 Hz, 1H), 7.02–6.99 (m, 1H), 6.93 (t, J = 6.8 Hz, 1H), 6.71 (dd, J = 3.6, 1.6 Hz, 1H); 13C{1H} NMR (100 MHz, CDCl3) δ 148.3, 144.3, 138.4, 134.3, 127.9, 125.5, 123.7, 117.5, 116.4, 115.7, 115.0, 114.4, 112.6, 112.2, 111.6, 101.0, 72.4; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C18H11N4O 299.0927, found 299.0920.
Pharmaceuticals 15 01395 i0155-(Thiophen-2-yl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5n). Yellow solid, m.p.: 220.8–221.5 °C (22.8 mg, 66%); 1H NMR (400 MHz, CDCl3) δ 8.69 (d, J = 6.8 Hz, 1H), 8.04–7.99 (m, 1H), 7.93 (d, J = 4.4 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 5.2 Hz, 1H), 7.26-7.22 (m, 2H), 7.17–7.12 (m, 1H), 6.97 (t, J = 3.2 Hz, 1H), 6.91 (t, J = 7.2 Hz, 1H); 13C{1H} NMR (100 MHz, CDCl3) δ 138.2, 138.0, 136.6, 129.0, 128.5, 128.0, 127.7, 125.4, 123.7, 117.4, 116.4, 115.6, 114.3, 112.7, 111.3, 101.4, 72.2; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C18H11N4S 315.0699, found 315.0714.
Pharmaceuticals 15 01395 i0165-(Pyridin-3-yl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5o). Yellow solid, m.p.: 238.3–238.9 °C (30.6 mg, 90%); 1H NMR (400 MHz, CDCl3) δ 9.18 (s, 1H), 8.86–8.81 (m, 1H), 8.71 (d, J = 6.4 Hz, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.60–7.51 (m, 2H), 7.29 (t, J = 7.9 Hz, 1H), 7.19–7.14 (m, 1H), 6.97–6.89 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 151.4, 149.7, 141.1, 138.3, 136.0, 130.2, 128.4, 127.8, 125.7, 123.60, 123.55, 117.5, 116.2, 115.8, 113.7, 112.9, 111.9, 101.6, 72.4; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C19H12N5 310.1087, found 310.1091.
Pharmaceuticals 15 01395 i0175-(2-Methoxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5p). Brown solid, m.p.: 245.4–245.9 °C (27.9 mg, 75%); 1H NMR (400 MHz, CDCl3) δ 8.73 (d, J = 6.8 Hz, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.62–7.51 (m, 2H), 7.28–7.22 (m, 1H), 7.17 (t, J = 7.4 Hz, 1H), 7.15–7.08 (m, 2H), 7.08–7.04 (m, 1H), 6.98 (t, J = 6.8 Hz, 1H), 6.84 (t, J = 3.0 Hz, 1H), 3.77 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 157.5, 142.8, 137.9, 132.0, 131.0, 128.3, 126.9, 125.1, 123.7, 123.1, 121.2, 117.3, 116.6, 114.9, 114.7, 112.5, 111.8, 111.4, 100.8, 72.1, 55.8; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C21H15N4O 339.1240, found 339.1243.
Pharmaceuticals 15 01395 i0185-(3-Methoxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5q). Yellow solid, m.p.: 182.3–182.9 °C (27.5 mg, 74%); 1H NMR (400 MHz, CDCl3) δ 8.72 (d, J = 6.8 Hz, 1H), 7.73 (d, J = 9.2 Hz, 1H), 7.64–7.60 (m, 1H), 7.53–7.45 (m, 2H), 7.41 (s, 1H), 7.25 (t, J = 8.0 Hz, 1H), 7.16–7.10 (m, 2H), 6.93–6.86 (m, 2H), 3.90 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 160.0, 143.9, 138.0, 135.2, 130.1, 128.5, 127.7, 125.2, 123.6, 120.8, 117.4, 116.5, 116.4, 115.1, 114.5, 114.2, 112.6, 111.5, 101.2, 72.1, 55.5; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C21H15N4O 339.1240, found 339.1241.
Pharmaceuticals 15 01395 i0195-(2-Hydroxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5r). Yellow solid, m.p.: 248.4–249.1 °C (24.3 mg, 68%); 1H NMR (400 MHz, CDCl3) δ 9.71 (s, 1H), 8.59 (d, J = 6.8 Hz, 1H), 7.98 (d, J = 7.6 Hz, 1H), 7.95–7.92 (m, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 7.2 Hz, 1H), 7.08 (t, J = 8.0 Hz, 1H), 6.99–6.93 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 156.3, 142.2, 138.3, 132.6, 127.9, 127.7, 126.4, 125.6, 123.0, 119.7, 118.3, 117.7, 117.3, 116.0, 115.9, 115.4, 113.3, 111.9, 102.1, 72.8; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H13N4O 325.1084, found 325.1074.
Pharmaceuticals 15 01395 i0205-(3-Hydroxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5s). Green solid, m.p.: 318.7–319.3 °C (28.9 mg, 81%); 1H NMR (400 MHz, DMSO-d6) δ 9.93 (s, 1H), 8.85 (d, J = 6.8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.69–7.66 (m, 1H), 7.49-7.41 (m, 2H), 7.34 (d, J = 7.6 Hz, 1H), 7.29 (s, 1H), 7.13 (t, J = 6.8 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.99–6.93 (m, 2H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 158.2, 144.2, 137.9, 134.9, 130.6, 128.4, 127.3, 127.1, 124.5, 119.6, 118.2, 117.3, 116.5, 115.9, 115.7, 115.3, 114.1, 110.8, 100.6, 70.8; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H13N4O 325.1084, found 325.1090.
Pharmaceuticals 15 01395 i0215-(2-Fluorophenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5t). Yellow solid, m.p.: 220.2–220.7 °C (19.0 mg, 53%); 1H NMR (400 MHz, CDCl3) δ 8.72 (d, J = 6.8 Hz, 1H), 7.78–7.69 (m, 2H), 7.67–7.56 (m, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.36–7.22 (m, 3H), 7.19–7.15 (m, 1H), 6.95–6.88 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 161.5, 159.0, 139.6, 138.2, 132.5 (d, J = 8.2 Hz), 131.3 (d, J = 2.4 Hz), 128.1, 127.2, 125.5, 125.0 (d, J = 3.4 Hz), 123.7, 117.5, 116.45, 116.41, 115.3, 114.4 (d, J = 2.2 Hz), 112.7, 112.1, 101.3, 72.3; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H12FN4 327.1041, found 327.1040.
Pharmaceuticals 15 01395 i0225-(2-Chlorophenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5u). Yellow solid, m.p.: 249.2–249.7 °C (25.3 mg, 67%); 1H NMR (400 MHz, CDCl3) δ 8.72 (d, J = 6.8 Hz, 1H), 7.76(d, J = 8.8 Hz, 1H), 7.65–7.59 (m, 2H), 7.56 (t, J = 7.6, 1H), 7.51 (t, J = 7.6, 1H), 7.31–7.26 (m, 1H), 7.20–7.14 (m, 1H), 7.06–7.01 (m, 1H), 6.94–6.88 (m 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 141.6, 138.2, 133.6, 133.1, 131.7, 131.1, 130.3, 128.0, 127.6, 127.0, 125.5, 123.7, 117.4, 116.4, 115.5, 114.2, 112.7, 112.1, 101.3, 72.3; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H12ClN4 343.0745, found 343.0743.
Pharmaceuticals 15 01395 i0235-(3-Chlorophenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5v). Yellow solid, m.p.: 243.1–243.8 °C (26.8 mg, 71%); 1H NMR (400 MHz, CDCl3) δ 8.71 (d, J = 6.4 Hz, 1H), 7.90 (s, 1H), 7.81 (d, J = 6.8 Hz, 1H), 7.74 (d, J = 9.2 Hz, 1H), 7.62–7.50 (m, 3H), 7.29 (d, J = 7.2 Hz, 1H), 7.19–7.13 (m, 1H), 6.97–6.89 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 142.5, 138.2, 135.6, 135.1, 130.7, 130.2, 129.0, 128.4, 127.7, 126.7, 125.5, 123.6, 117.5, 116.3, 115.5, 114.1, 112.8, 111.8, 101.5, 72.3; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H12ClN4 343.0745, found 343.0739.
Pharmaceuticals 15 01395 i0245-(2-Bromophenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5w). Yellow solid, m.p.: 222.1–222.6 °C (19.6 mg, 46%); 1H NMR (400 MHz, CDCl3) δ 8.74 (d, J = 6.8 Hz, 1H), 7.93–7.87 (m, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.64–7.58 (m, 3H), 7.31–7.27 (m, 1H), 7.16 (d, J = 3.6 Hz, 1H), 6.96–6.88 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 138.1, 134.0, 130.6, 129.0, 128.7, 127.7, 125.3, 123.6, 120.6, 117.5, 116.5, 115.2, 114.4, 112.7, 111.6, 104.0, 101.6, 101.3, 72.2; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H12BrN4 387.0240, found 387.0208.
Pharmaceuticals 15 01395 i0255-(1H-Imidazol-2-yl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5x). Dark green solid, m.p.: 304.1–304.9 °C (24.3 mg, 74%); 1H NMR (400 MHz, DMSO-d6) δ 13.38 (s, 1H), 9.46–9.39 (m, 1H), 9.05 (d, J = 6.8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.63 (s, 1H), 7.48 (t, J = 5.8 Hz, 1H), 7.36 (s, 1H), 7.24 (t, J = 6.0 Hz, 1H), 7.09–7.03 (m, 1H), 7.00–6.94 (m, 1H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 141.1, 138.1, 133.0, 130.7, 127.3, 127.1, 124.8, 120.7, 117.2, 116.4, 115.6, 113.7, 110.7, 100.2, 71.0; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C17H11N6 299.1040, found 299.1027.
Pharmaceuticals 15 01395 i0265-(2-Hydroxy-5-methoxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5y). Yellow solid, m.p.: 240.3–240.7 °C (14.4 mg, 37%); 1H NMR (400 MHz, DMSO-d6) δ 9.69 (s, 1H), 8.88 (d, J = 6.6 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.20 (s, 1H), 7.16–7.04 (m, 3H), 7.00 (d, J = 8.8 Hz, 1H), 6.95–6.89 (m, 2H), 3.73 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 152.7, 150.0, 142.0, 138.3, 127.8, 126.5, 125.6, 123.1, 119.2, 119.0, 117.7, 116.0, 115.3, 113.2, 112.4, 111.9, 102.1, 72.7, 56.0; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C21H15N4O2 355.1190, found 355.1201.
Pharmaceuticals 15 01395 i0275-(2-Hydroxy-4-methoxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5z). Yellow solid, m.p.: 235.7–236.4 °C (34.7 mg, 89%); 1H NMR (400 MHz, CDCl3) δ 10.31 (s, 1H), 8.57 (d, J = 6.8 Hz, 1H), 7.96 (s, 1H), 7.94 (d, J = 7.2 Hz, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.31–7.27 (m, 1H), 7.16 (d, J = 2.4 Hz, 1H), 6.98–6.93 (m, 2H), 6.70 (d, J = 2.4 Hz, 1H), 6.64 (dd, J = 8.8 Hz, 2.4 Hz, 1H), 3.90 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 162.9, 158.6, 142.7, 138.0, 128.8, 127.9, 126.3, 125.2, 122.9, 117.6, 116.0, 115.8, 115.4, 113.1, 111.3, 109.9, 106.8, 102.5, 102.0, 72.6, 55.5; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C21H15N4O2 355.1190, found 355.1194.
Pharmaceuticals 15 01395 i0285-(2-Hydroxy-4,5-dimethoxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5aa). Yellow solid, m.p.: 243.7–244.4 °C (29.6 mg, 70%); 1H NMR (400 MHz, CDCl3) δ 9.86 (s, 1H), 8.56 (d, J = 6.8 Hz, 1H), 7.98–7.95 (m, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.45 (s, 1H), 7.31–7.27 (m, 1H), 7.16 (d, J = 3.6 Hz, 1H), 6.99–6.92 (m, 2H), 6.72 (s, 1H), 3.98 (s, 3H), 3.89 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3) δ 152.7, 152.1, 142.7, 142.4, 137.9, 127.6, 126.4, 125.3, 122.8, 117.6, 115.9, 115.2, 113.2, 111.1, 110.4, 108.2, 102.0, 101.9, 72.6, 56.8, 56.1; HRMS (ESI-QTOF) m/z [M+Na]+ calcd. for C22H16N4NaO3 407.1115, found 407.1140.
Pharmaceuticals 15 01395 i0295-(5-Chloro-2-hydroxyphenyl)pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (5ab). Brown solid, m.p.: 276.5–277.3 °C (15.0 mg, 38%); 1H NMR (400 MHz, DMSO-d6) δ 10.49 (s, 1H), 8.88 (d, J = 6.8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.62 (s, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 7.22 (s, 1H), 7.14–7.05 (m, 2H), 6.95–6.90 (m, 2H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 154.6, 141.6, 137.6, 131.6, 130.4, 127.7, 126.8, 125.9, 124.3, 122.8, 122.4, 118.0, 116.9, 116.1, 115.4, 115.0, 113.7, 110.8, 99.9, 70.4; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C20H12ClN4O 359.0694, found 359.0693.

3.1.3. Synthesis of 8

A mixture of 4 (25.0 mg, 0.11 mmol, 1.0 equiv) and DMFDMA (17.3 μL, 0.13 mmol, 1.2 equiv) in toluene (1 mL) was stirred at 130 °C for 24 h. The reaction mixture was concentrated under reduced pressure to give the crude residue, which was purified by silica gel column chromatography (hexane:EtOAc:dichloromethane = 5:1:2) to afford 8 (23.8 mg, 93%) as a green solid.
Pharmaceuticals 15 01395 i030Pyrrolo[1′,2′:1,6]pyrimido[5,4-b]indolizine-12-carbonitrile (8). Green solid, m.p.: 248.8–249.5 °C (23.8 mg, 93%); 1H NMR (400 MHz, CDCl3) δ 8.63 (d, J = 6.8 Hz, 1H), 8.55 (s, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.51–7.45 (m, 1H), 7.29–7.21 (m, 1H), 7.01 (d, J = 3.6 Hz, 1H), 6.89–6.95 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ 137.9, 134.5, 127.7, 126.1, 125.3, 123.4, 117.4, 116.3, 115.9, 113.2, 112.8, 112.5, 100.8, 72.4; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C14H9N4 233.0822, found 233.0820.

3.1.4. Synthesis of 9

Compound 9 was prepared with 2-pyridylacetonitrile (472.1 μL, 4.23 mmol, 1.0 equiv) by following the same procedures for the synthesis of 4.
Pharmaceuticals 15 01395 i0313-Amino-2-(1H-indol-2-yl)indolizine-1-carbonitrile (9). Green solid, m.p.: 223.9–224.4 °C (967.6 mg, 84%); 1H NMR (400 MHz, DMSO-d6) δ 11.20 (s, 1H), 8.30 (d, J = 6.8 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 7.08–7.00 (m, 2H), 6.91 (t, J = 6.8 Hz, 1H), 6.83 (s, 1H), 5.40 (s, 2H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 137.1, 133.8, 131.0, 128.7, 128.3, 123.1, 121.7, 121.5, 120.1, 119.8, 117.9, 116.9, 112.9, 111.9, 106.0, 100.7, 77.0; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C17H13N4 273.1135, found 273.1140.

3.1.5. Synthesis of 10

Compounds 10 were prepared with 9 (30.0 mg, 0.11 mmol, 1.0 equiv) by following the same procedures for the synthesis of 5.
Pharmaceuticals 15 01395 i0327-Phenyl-12H-indolizino[2′,3′:5,6]pyrido[4,3-b]indole-13-carbonitrile (10a). Yellow solid, m.p.: 329.6–330.1 °C (17.3 mg, 44%); 1H NMR (400 MHz, DMSO-d6) δ 12.50 (s, 1H), 9.13 (d, J = 6.8 Hz, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.86–7.79 (m, 3H), 7.68–7.62 (m, 2H), 7.59 (d, J = 8.4 Hz, 1H), 7.52–7.41 (m, 2H), 7.16–7.09 (m, 1H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 149.6, 140.6, 140.5, 140.4, 137.9, 136.9, 129.6, 129.3, 129.2, 128.9, 126.1, 125.5, 121.8, 121.3, 120.7, 117.5, 117.0, 114.2, 113.1, 106.2, 69.0; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C24H15N4 359.1291, found 359.1293.
Pharmaceuticals 15 01395 i0337-(4-Methoxyphenyl)-12H-indolizino[2′,3′:5,6]pyrido[4,3-b]indole-13-carbonitrile (10b). Green solid, m.p.: 356.3–356.8 °C (24.4 mg, 57%); 1H NMR (400 MHz, DMSO-d6) δ 12.45 (s, 1H), 9.10 (d, J = 6.8 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.81 (d, J = 6.8 Hz, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.63–7.55 (m, 2H), 7.45 (t, J = 7.6 Hz, 1H), 7.19 (d, J = 8.8 Hz, 2H), 7.17–7.08 (m, 2H), 3.91 (s, 3H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 164.9, 154.3, 145.2, 145.1, 142.7, 141.7, 137.7, 135.8, 134.0, 130.8, 130.2, 126.7, 126.2, 125.5, 122.3, 121.8, 119.0, 117.9, 110.7, 73.7, 60.5; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C25H17N4O 389.1397, found 389.1398.
Pharmaceuticals 15 01395 i0347-(4-Bromophenyl)-12H-indolizino[2′,3′:5,6]pyrido[4,3-b]indole-13-carbonitrile (10c). Brown solid, m.p.: 352.1–352.9 °C (23.6 mg, 49%); 1H NMR (400 MHz, DMSO-d6) δ 12.50 (s, 1H), 9.09 (d, J = 6.8 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.87–7.82 (m, 3H), 7.79 (d, J = 8.4 Hz, 2H), 7.59 (t, J = 7.6 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.46 (t, J = 7.0 Hz, 1H), 7.20–7.08 (m, 2H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 148.2, 141.1, 140.4, 137.5, 136.4, 133.1, 131.5, 131.2, 129.5, 128.6, 126.2, 125.6, 122.9, 121.8, 121.1, 120.7, 117.6, 116.9, 115.1, 113.1, 106.7, 69.2; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C24H14BrN4 437.0396, found 437.0398.
Pharmaceuticals 15 01395 i0357-(Thiophen-2-yl)-12H-indolizino[2′,3′:5,6]pyrido[4,3-b]indole-13-carbonitrile (10d). Yellow solid, m.p.: 326.8–327.3 °C (33.7 mg, 84%); 1H NMR (400 MHz, DMSO-d6) δ 12.54 (s, 1H), 9.09 (d, J = 6.8 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.87 (d, J = 5.2 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.79–7.73 (m, 1H), 7.62 (t, J = 7.8 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.39–7.34 (m, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.17 (t, J = 7.2 Hz, 1H); 13C{1H} NMR (100 MHz, DMSO-d6) δ 142.8, 142.7, 140.7, 140.5, 137.6, 137.2, 129.7, 128.6, 128.5, 128.0, 126.4, 125.5, 121.7, 121.4, 120.9, 117.6, 116.9, 114.3, 113.4, 113.3, 106.5, 69.2; HRMS (ESI-QTOF) m/z [M+H]+ calcd. for C22H13N4S 365.0855, found 365.0879.

3.2. Bioassay

3.2.1. Cell Culture

HepG2, Huh7, H1299, HT29, AGS and A549 cells were purchased from the Korean Cell Line Bank (Seoul, Korea) and HaCaT cells were obtained from Prof. Sohee Kwon (Yonsei University, Korea). Liver cancer cells (HepG2), human keratinocyte cells (HaCaT), and lung cancer cells (A549) were grown in DMEM high-glucose medium, liver cancer cells (Huh7) and non-small cell lung cancer cells (H1299) were grown in RPMI 1640, and gastric cancer cells (AGS) were grown in Coon’s modified F12 medium. All media were supplemented with 10% FBS, 100 Units/mL penicillin, and 100 μg/mL streptomycin. All cells were incubated at 37 °C, 5% CO2 and 95% humidity.

3.2.2. Cell Viability Assay

Cell viability assay was conducted using Cell Titer 96® AQueous One Solution Cell proliferation Assay kit (Promega, Madison, WI, USA). Five cancer cells and HaCaT cells were plated in 96-well microplates with growth medium for 24 h. When cell confluency reached ~30%, cells were treated with DMSO (vehicle) and test compounds. The medium and test compounds were replaced every 24 h. To measure cell viability, the cells were incubated with MTS solution for 1 h. The absorbance was measured by using Infinite M200 microplate reader (Tecan, Männedorf, Switzerland) at 490 nm.

3.2.3. In Vitro Wound-Healing Assay

The suppressive effect of 5r on cell migration was assessed through in vitro wound-healing assay. HepG2 and Huh7 cells were grown to approximately 100% confluence to form a monolayer in a 96-well microplate. Wounds were formed through 96-well wound maker (Essen BioScience, Ann Arbor, MI, USA). Then, growth medium was removed and washed out twice with phosphate-buffered saline (PBS) and incubated with 200 μL of DMEM and RPMI 1640 medium containing 5r or vehicle (DMSO). Images of the wound area were taken by using IncuCyte ZOOM (Essen BioScience, Ann Arbor MI, USA), and the percentage of wound closure was measured by using IncuCyte software.

3.2.4. Caspase-3 Activity Assay

HepG2 and Huh7 cells were plated in 96-black-well plate to about 40% confluence, and then 5r was treated for 24 h. To assess activity of caspase-3, the growth medium was changed with 100 μL of PBS containing 1 μM caspase-3 substrate, NucView 488, and incubated at room temperature. After 20 min, 1 μM Hoechst 33342 was treated to stain the cells. Activity of caspase-3 was suppressed by Ac-DEVD-CHO, a selective caspase-3 inhibitor. FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany) was used to assess the fluorescence of NucView 488 and Hoechst, and Lionheart FX Automated Microscope (BioTek, Winooski, VT, USA) was used to acquire the fluorescence microscopy images.

3.2.5. Western Blot Analysis

For Western blot analysis, HepG2 and Huh7 cells were lysed with RIPA buffer (50 mM Tris-HCl, PH 7.4, 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, and protease inhibitor). Lysed samples were centrifuged at 13,000 RPM for 20 min at 4 °C to remove the cell debris, and equal amounts (60 μg protein/lane) of supernatant protein were divided by 4–12% Tris Glycine Precast Gel (KOMA BIOTECH, Seoul, Korea). Then, PVDF membranes (Millipore, Billerica, MA, USA) were used to transfer the separated proteins. Membrane blocking was performed by Tris-buffered saline with 0.1% Tween 20 (TBST) containing 5% bovine serum albumin (BSA) at room temperature for 50 min. The membranes were incubated with primary antibodies overnight at 4 °C with the indicated primary antibodies: anti-cleaved PARP (BD Biosciences) and anti-β-actin (Santa Cruz Biotechnology, Dallas, TX, USA). After incubating overnight, the membranes were washed out three times in 0.1% TBST and incubated with horseradish-peroxidase-conjugated secondary antibodies for 1 h. After 1 h, membranes were detected by using ECL Plus Western blotting detection system (GE Healthcare, Piscataway, NJ, USA).

3.2.6. Flow Cytometry Analysis

HepG2 cells were grown to approximately 40% confluence in a 6-well plate and then 5r was treated for 24 h. After 24 h, HepG2 cells were washed out twice with PBS and centrifuged at 1000 RPM for 2 min at room temperature. The cells were stained with propidium iodide for 15 min and then cell cycle phases were measured by using FACS (Beckman Coulter, Fullerton, CA, USA).

4. Conclusions

In summary, a new indolizine fused with pyrrolo[1,2-c]pyrimidine was designed and synthesized via one-pot three-component coupling followed by oxidative cyclization. This two-step protocol enabled the rapid construction of a novel tetracyclic heteroaromatic chemical library. The biological investigation of these compounds in five cancer cells revealed that some reduced the cell viability of HepG2 and Huh7 cells more strongly than those of the other three cancer cells. The structure–activity relationship study of these compounds led us to identify 5r showing potent and selective anticancer activity against liver cancer cells (HepG2 and Huh7). Notably, 5r had a weak inhibitory effect on the cell viability in nontumorigenic human keratinocytes (HaCaT) cells. Moreover, 5r strongly inhibited cell migration and induced apoptosis through increase of caspase-3 activity and cleavage of PARP in a dose-dependent manner in HepG2 and Huh7 cells. In addition, co-treatment of 5r with gemcitabine showed additional effect on cell viability in HegG2 and Huh7 cells. Taken together, these results suggest that 5r could be used for the development of novel anticancer agents with distinctive polyheterocyclic pharmacophore to overcome the limitations of current liver cancer therapeutics.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph15111395/s1; 1H and 13C NMR spectra of synthesized compounds.

Author Contributions

Conceptualizations, W.N. and I.K.; methodology, S.N. and Y.L.: validation, S.N. and Y.L.; formal analysis, S.N., Y.L. and S.-H.P.; investigation, S.N. and Y.L.; data curation, S.N. and Y.L.; writing-original draft preparation, S.N., Y.L., W.N. and I.K.; writing-review and editing, W.N. and I.K.; visualization, W.N. and I.K.; supervision: W.N. and I.K.; project administration, W.N. and I.K.; funding acquisition, I.K. All authors have read and agreed to the published version of the manuscript.

Funding

We thank the National Research Foundation of Korea (NRF-2018R1A6A1A03023718 and NRF-2020R1A2C2005961) for generous financial support.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article and Supplementary Material.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ibarra, I.A.; Islas-Jácome, A.; González-Zamora, E. Synthesis of polyheterocycles via multicomponent reactions. Org. Biomol. Chem. 2018, 16, 1402–1418. [Google Scholar] [CrossRef] [PubMed]
  2. Zheng, L.; Hua, R. Recent Advances in Construction of Polycyclic Natural Product Scaffolds via One-Pot Reactions Involving Alkyne Annulation. Front. Chem. 2020, 8, 580355. [Google Scholar] [CrossRef] [PubMed]
  3. Jung, Y.; Kim, I. Deformylative Intramolecular Hydroarylation: Synthesis of Benzo[e]pyrido [1,2-a]indoles. Org. Lett. 2015, 17, 4600–4603. [Google Scholar] [CrossRef] [PubMed]
  4. Bae, G.H.; Kim, S.; Lee, N.K.; Dagar, A.; Lee, J.H.; Lee, J.; Kim, I. Facile approach to benzo[d]imidazole-pyrrolo [1,2-a]pyrazine hybrid structures through double cyclodehydration and aromatization and their unique optical properties with blue emission. RSC Adv. 2020, 10, 7265–7288. [Google Scholar] [CrossRef] [Green Version]
  5. Joshi, D.R.; Seo, Y.; Heo, Y.; Park, S.-H.; Lee, Y.; Namkung, W.; Kim, I. Domino [4+2] Annulation Access to Quinone–Indolizine Hybrids: Anticancer N-Fused Polycycles. J. Org. Chem. 2020, 85, 10994–11005. [Google Scholar] [CrossRef]
  6. Kim, S.; Park, J.; Joshi, D.R.; Lee, N.K.; Pham, H.L.B.; Chung, L.K.; Kang, M.; Kim, Y.; Kim, I.; Lee, J. Benzofuro [2,3-c]isoquinolines as novel AIEgens: Modulation of AIE characteristics by a single methoxy group. Dyes Pigm. 2022, 206, 110584. [Google Scholar] [CrossRef]
  7. Anwanwan, D.; Singh, S.K.; Singh, S.; Saikam, V.; Singh, R. Challenges in liver cancer and possible treatment approaches. Biochim. Biophys. Acta Rev. Cancer 2020, 1873, 188314. [Google Scholar] [CrossRef]
  8. Starley, B.Q.; Calcagno, C.J.; Harrison, S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010, 51, 1820–1832. [Google Scholar] [CrossRef]
  9. Center, M.M.; Jemal, A. International Trends in Liver Cancer Incidence Rates. Cancer Epidemiol. Biomark. Prev. 2011, 20, 2362–2368. [Google Scholar] [CrossRef] [Green Version]
  10. El-Serag, H.B.; Marrero, J.A.; Rudolph, L.; Reddy, K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134, 1752–1763. [Google Scholar] [CrossRef]
  11. Balogh, J.; Victor, D., III; Asham, E.H.; Burroughs, S.G.; Boktour, M.; Saharia, A.; Li, X.; Ghobrial, R.M.; Monsour, H.P., Jr. Hepatocellular carcinoma: A review. J. Hepatocell. Carcinoma 2016, 3, 41–53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Martinez-Ariza, G.; Mehari, B.T.; Pinho, L.A.; Foley, C.; Day, K.; Jewett, J.C.; Hulme, C. Synthesis of fluorescent heterocycles via a Knoevenagel/[4+1]-cycloaddition cascade using acetyl cyanide. Org. Biomol. Chem. 2017, 15, 6076–6079. [Google Scholar] [CrossRef] [PubMed]
  13. Sharma, V.; Kumar, V. Indolizine: A biologically active moiety. Med. Chem. Res. 2014, 23, 3593–3606. [Google Scholar] [CrossRef]
  14. Kim, J.T.; Hamilton, A.D.; Bailey, C.M.; Domaoal, R.A.; Wang, L.; Anderson, K.S.; Jorgensen, W.L. FEP-Guided Selection of Bicyclic Heterocycles in Lead Optimization for Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. J. Am. Chem. Soc. 2006, 128, 15372–15373. [Google Scholar] [CrossRef] [PubMed]
  15. Charvin, D.; Pomel, V.; Ortiz, M.; Frauli, M.; Scheffler, S.; Steinberg, E.; Baron, L.; Deshons, L.; Rudigier, R.; Thiaec, D.; et al. Discovery, structure–activity relationship, and antiparkinsonian effect of a potent and brain-penetrant chemical series of positive allosteric modulators of metabotropic glutamate receptor 4. J. Med. Chem. 2017, 60, 8515–8537. [Google Scholar] [CrossRef]
  16. Bedard, N.; Foley, C.; Davis, G.J.; Jewett, J.C.; Hulme, C. Sequential Knoevenagel [4+1] Cycloaddition–Condensation–Aza-Friedel–Crafts Intramolecular Cyclization: A 4-Center-3-Component Reaction Toward Tunable Fluorescent Indolizine Tetracycles. J. Org. Chem. 2021, 86, 17550–17559. [Google Scholar] [CrossRef]
  17. Agarwal, P.K.; Sawant, D.; Sharma, S.; Kundu, B. New route to the synthesis of the isocryptolepine alkaloid and its related skeletons using a modified Pictet–Spengler reaction. Eur. J. Org. Chem. 2009, 2009, 292–303. [Google Scholar] [CrossRef]
  18. Guo, S.; Tao, L.; Zhang, W.; Zhang, X.; Fan, X. Regioselective synthesis of indolo [1,2-c]quinazolines and 11H-indolo[3,2-c]quinolines via copper-catalyzed cascade reactions of 2-(2-bromoaryl)-1H-indoles with aldehydes and aqueous ammonia. J. Org. Chem. 2015, 80, 10955–10964. [Google Scholar] [CrossRef]
  19. Guchelaar, H.; Richel, D.; Van Knapen, A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat. Rev. 1996, 22, 15–31. [Google Scholar] [CrossRef]
  20. Graziadei, I.; Kelly, T.; Schirmer, M.; Geisen, F.H.; Vogel, W.; Konwalinka, G. Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′,2′-difluorodeoxycytidine on human hepatoma HepG2 cells. J. Hepatol. 1998, 28, 504–509. [Google Scholar] [CrossRef]
  21. Yang, T.S.; Lin, Y.C.; Chen, J.S.; Wang, H.M.; Wang, C.H. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000, 89, 750–756. [Google Scholar] [CrossRef]
  22. Ulrich-Pur, H.; Kornek, G.V.; Fiebiger, W.; Schüll, B.; Raderer, M.; Scheithauer, W. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology 2001, 60, 313–315. [Google Scholar] [CrossRef] [PubMed]
  23. Kubicka, S.; Rudolph, K.L.; Tietze, M.K.; Lorenz, M.; Manns, M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato-Gastroenterol. 2001, 48, 783–789. [Google Scholar]
  24. Fuchs, C.S.; Clark, J.W.; Ryan, D.P.; Kulke, M.H.; Kim, H.; Earle, C.C.; Vincitore, M.; Mayer, R.J.; Stuart, K.E. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002, 94, 3186–3191. [Google Scholar] [CrossRef] [PubMed]
  25. Guan, Z.; Wang, Y.; Maoleekoonpairoj, S.; Chen, Z.; Kim, W.; Ratanatharathorn, V.; Reece, W.; Kim, T.; Lehnert, M. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br. J. Cancer 2003, 89, 1865–1869. [Google Scholar] [CrossRef]
  26. Parikh, P.; Fuloria, J.; Babu, G.; Doval, D.; Awasthy, B.; Pai, V.; Prabhakaran, P.; Benson, A. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop. Gastroenterol. 2005, 26, 115–118. [Google Scholar]
Pharmaceuticals 15 01395 g001 550
Figure 1. Some Fused Heterocyclic Systems Developed by Us.
Figure 1. Some Fused Heterocyclic Systems Developed by Us.
Pharmaceuticals 15 01395 g001
Pharmaceuticals 15 01395 sch001 550
Scheme 1. Synthetic Plan.
Scheme 1. Synthetic Plan.
Pharmaceuticals 15 01395 sch001
Pharmaceuticals 15 01395 sch002 550
Scheme 2. Synthesis of 5a, 8, and 10.
Scheme 2. Synthesis of 5a, 8, and 10.
Pharmaceuticals 15 01395 sch002
Pharmaceuticals 15 01395 g002 550
Figure 2. Effect of 5r on cell viability in HepG2, Huh7, AGS, H1299, A549, HaCaT, NIH3T3, and HEK293T cells. (A–H) HepG2, Huh7, AGS, H1299, A549, HaCaT, NIH3T3, and HEK293T cells were cultured with 5r at the indicated concentrations for 72 h, and medium was replaced every 24 h with freshly added 5r. Cell viability was measured by MTS analysis (mean ± S.D., n = 5). * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 2. Effect of 5r on cell viability in HepG2, Huh7, AGS, H1299, A549, HaCaT, NIH3T3, and HEK293T cells. (A–H) HepG2, Huh7, AGS, H1299, A549, HaCaT, NIH3T3, and HEK293T cells were cultured with 5r at the indicated concentrations for 72 h, and medium was replaced every 24 h with freshly added 5r. Cell viability was measured by MTS analysis (mean ± S.D., n = 5). * p < 0.05, ** p < 0.01, *** p < 0.001.
Pharmaceuticals 15 01395 g002
Pharmaceuticals 15 01395 g003 550
Figure 3. Inhibitory effect of 5r on cell migration in HepG2 and Huh7 cells. (A,B) In vitro wound-healing assay was performed in HepG2 and Huh7 cells (mean ± S.D., n = 3). HepG2 and Huh7 cells were treated with the indicated concentrations of 5r, and time-lapse images were acquired every 2 h after wound infliction. (C,D) Representative images were taken at 0, 48, or 72 h following administration of 5r at the indicated concentrations.
Figure 3. Inhibitory effect of 5r on cell migration in HepG2 and Huh7 cells. (A,B) In vitro wound-healing assay was performed in HepG2 and Huh7 cells (mean ± S.D., n = 3). HepG2 and Huh7 cells were treated with the indicated concentrations of 5r, and time-lapse images were acquired every 2 h after wound infliction. (C,D) Representative images were taken at 0, 48, or 72 h following administration of 5r at the indicated concentrations.
Pharmaceuticals 15 01395 g003
Pharmaceuticals 15 01395 g004a 550Pharmaceuticals 15 01395 g004b 550
Figure 4. Effect of 5r on activity of caspase-3 and cleavage of PARP in HepG2 and Huh7 cells. (A,B) HepG2 and Huh7 cells were incubated with 3 µM 5r for 24 h and then incubated with 1 µM caspase-3 substrate (green) and 1 µM Hoechst 33,342 (blue) for 20 min before image acquisition. (C,D) Cells were cultured with 5r at the indicated concentrations for 24 h and then 1 μM caspase-3 substrate was treated for 20 min. Caspase-3 was inhibited by 20 μM Ac-DEVD-CHO (mean ± S.D., n = 3). (E,F) Cells were cultured with 5r at the indicated concentrations for 24 h, and expression level of PARP, cleaved-PARP and β-actin were measured by Western blot analysis. (G,H) Cleaved PARP protein intensities were normalized to β-actin (mean ± S.E., n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 4. Effect of 5r on activity of caspase-3 and cleavage of PARP in HepG2 and Huh7 cells. (A,B) HepG2 and Huh7 cells were incubated with 3 µM 5r for 24 h and then incubated with 1 µM caspase-3 substrate (green) and 1 µM Hoechst 33,342 (blue) for 20 min before image acquisition. (C,D) Cells were cultured with 5r at the indicated concentrations for 24 h and then 1 μM caspase-3 substrate was treated for 20 min. Caspase-3 was inhibited by 20 μM Ac-DEVD-CHO (mean ± S.D., n = 3). (E,F) Cells were cultured with 5r at the indicated concentrations for 24 h, and expression level of PARP, cleaved-PARP and β-actin were measured by Western blot analysis. (G,H) Cleaved PARP protein intensities were normalized to β-actin (mean ± S.E., n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001.
Pharmaceuticals 15 01395 g004aPharmaceuticals 15 01395 g004b
Pharmaceuticals 15 01395 g005 550
Figure 5. Effect of 5r on cell cycle in HepG2 cells. (A,B) HepG2 cells were treated with 3 µM 5r for 24 h and then cell cycle phases were measured by propidium iodide staining, followed by flow cytometry analysis.
Figure 5. Effect of 5r on cell cycle in HepG2 cells. (A,B) HepG2 cells were treated with 3 µM 5r for 24 h and then cell cycle phases were measured by propidium iodide staining, followed by flow cytometry analysis.
Pharmaceuticals 15 01395 g005
Pharmaceuticals 15 01395 g006 550
Figure 6. Combination effect of 5r and gemcitabine on cell viability in HepG2 and Huh7 cells. (A,B) HepG2 and Huh7 cells were cultured with the indicated concentrations of 5r and gemcitabine (0.3 μM) for 72 h, and medium was replaced every 24 h with freshly added 5r and gemcitabine. Cell viability was determined by MTS analysis (mean ± S.D., n = 5). ** p < 0.01, *** p < 0.001.
Figure 6. Combination effect of 5r and gemcitabine on cell viability in HepG2 and Huh7 cells. (A,B) HepG2 and Huh7 cells were cultured with the indicated concentrations of 5r and gemcitabine (0.3 μM) for 72 h, and medium was replaced every 24 h with freshly added 5r and gemcitabine. Cell viability was determined by MTS analysis (mean ± S.D., n = 5). ** p < 0.01, *** p < 0.001.
Pharmaceuticals 15 01395 g006
Table
Table 1. Synthesis of 5 a,b.
Table 1. Synthesis of 5 a,b.
Pharmaceuticals 15 01395 i036
Pharmaceuticals 15 01395 i037Pharmaceuticals 15 01395 i038Pharmaceuticals 15 01395 i039
5b (64%)5c (72%)5d (89%)
Pharmaceuticals 15 01395 i040Pharmaceuticals 15 01395 i041Pharmaceuticals 15 01395 i042
5e (64%)5f (66%)5g (81%)
Pharmaceuticals 15 01395 i043Pharmaceuticals 15 01395 i044Pharmaceuticals 15 01395 i045
5h (73%)5i (77%)5j (64%)
Pharmaceuticals 15 01395 i046Pharmaceuticals 15 01395 i047Pharmaceuticals 15 01395 i048
5k (87%)5l (71%)5m (90%)
Pharmaceuticals 15 01395 i049
5n (66%)
a A mixture of 4 (25.0 mg, 0.11 mmol, 1.0 equiv), ArCHO (1.2 equiv), and K2CO3 (2.0 equiv) in DMSO (2 mL) was stirred at 130 °C (microwave heating) for 30 min. b Isolated yield (%).
Table
Table 2. Cytotoxicity of 5, 8, and 10 in HepG2, H1299, HT29, AGS and A549 cells (mean, n = 3).
Table 2. Cytotoxicity of 5, 8, and 10 in HepG2, H1299, HT29, AGS and A549 cells (mean, n = 3).
Compound% Inhibition of Cell Viability at 10 μM
HepG2H1299HT29AGSA549
8<25<25<25<25<25
5a85.081.5<25<25<25
5b57.079.1<25<2525.5
5c76.794.044.056.047.1
5d57.383.4<25<25<25
5e37.789.0<25<2525.3
5f92.588.4<25<25<25
5g49.282.8<25<25<25
5h88.480.026.931.052.5
5i87.492.1<25<2536.7
5j42.252.8<25<25<25
5k90.683.828.8<2529.0
5l99.262.358.6<2546.9
5m64.081.9<25<25<25
5n98.970.348.4<2538.0
10a<2568.861.248.445.9
10b<25<25<25<25<25
10c39.6<25<25<25<25
Table
Table 3. Inhibitory effect of 5n–x and 10d on cell viability of HepG2, Huh7, and HaCaT cells (mean, n = 5).
Table 3. Inhibitory effect of 5n–x and 10d on cell viability of HepG2, Huh7, and HaCaT cells (mean, n = 5).
CompoundStructureIC50 (μM)
HepG2Huh7HaCaT
5nPharmaceuticals 15 01395 i0500.280.7513.34
5oPharmaceuticals 15 01395 i0512.001.473.98
5pPharmaceuticals 15 01395 i0523.422.2516.23
5qPharmaceuticals 15 01395 i0531.311.458.30
5rPharmaceuticals 15 01395 i0540.220.106.91
5sPharmaceuticals 15 01395 i0552.944.028.49
5tPharmaceuticals 15 01395 i0561.581.926.78
5uPharmaceuticals 15 01395 i0572.103.9511.52
5vPharmaceuticals 15 01395 i0581.481.3315.33
5wPharmaceuticals 15 01395 i0591.752.729.53
5xPharmaceuticals 15 01395 i0603.527.8524.05
10dPharmaceuticals 15 01395 i0612.270.600.81
Table
Table 4. Inhibitory effect of 5y–ab on cell viability of HepG2, Huh7, and HaCaT cells (mean, n = 5).
Table 4. Inhibitory effect of 5y–ab on cell viability of HepG2, Huh7, and HaCaT cells (mean, n = 5).
CompoundStructureIC50 (μM)
HepG2Huh7HaCaT
5rPharmaceuticals 15 01395 i0620.220.106.91
5yPharmaceuticals 15 01395 i0630.790.642.25
5zPharmaceuticals 15 01395 i0640.640.711.95
5aaPharmaceuticals 15 01395 i0651.170.872.21
5abPharmaceuticals 15 01395 i0660.840.712.30
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Nam, S.; Lee, Y.; Park, S.-H.; Namkung, W.; Kim, I. Synthesis and Biological Evaluation of a Fused Structure of Indolizine and Pyrrolo[1,2-c]pyrimidine: Identification of Its Potent Anticancer Activity against Liver Cancer Cells. Pharmaceuticals 2022, 15, 1395. https://doi.org/10.3390/ph15111395

AMA Style

Nam S, Lee Y, Park S-H, Namkung W, Kim I. Synthesis and Biological Evaluation of a Fused Structure of Indolizine and Pyrrolo[1,2-c]pyrimidine: Identification of Its Potent Anticancer Activity against Liver Cancer Cells. Pharmaceuticals. 2022; 15(11):1395. https://doi.org/10.3390/ph15111395

Chicago/Turabian Style

Nam, Seonghyeon, Yechan Lee, So-Hyeon Park, Wan Namkung, and Ikyon Kim. 2022. "Synthesis and Biological Evaluation of a Fused Structure of Indolizine and Pyrrolo[1,2-c]pyrimidine: Identification of Its Potent Anticancer Activity against Liver Cancer Cells" Pharmaceuticals 15, no. 11: 1395. https://doi.org/10.3390/ph15111395

APA Style

Nam, S., Lee, Y., Park, S. -H., Namkung, W., & Kim, I. (2022). Synthesis and Biological Evaluation of a Fused Structure of Indolizine and Pyrrolo[1,2-c]pyrimidine: Identification of Its Potent Anticancer Activity against Liver Cancer Cells. Pharmaceuticals, 15(11), 1395. https://doi.org/10.3390/ph15111395

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop